Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -95.28% | 8.82% | |||
| Depreciation & Amortization | 0.00% | -98.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -94.80% | -14.86% | |||
| Operating Income | 94.80% | 14.86% | |||
| Income Before Tax | 98.83% | -395.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 98.83% | -395.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 98.83% | -395.53% | |||
| EBIT | 94.80% | 14.86% | |||
| EBITDA | 106.93% | 6.07% | |||
| EPS Basic | 99.12% | -391.30% | |||
| Normalized Basic EPS | 90.91% | 26.67% | |||
| EPS Diluted | 99.12% | -391.30% | |||
| Normalized Diluted EPS | 90.91% | 26.67% | |||
| Average Basic Shares Outstanding | -0.06% | 3.05% | |||
| Average Diluted Shares Outstanding | -0.06% | 3.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||